Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

Minimal residual disease in acute lymphoblastic leukemia.

In patients with acute lymphoblastic leukemia (ALL), monitoring of minimal residual disease (MRD) offers a way to precisely assess early treatment response and detect relapse. Established methods to study MRD are flow cytometric detection of abnormal immunophenotypes, polymerase chain reaction (PCR) amplification of antigen-receptor genes, and PCR amplification of fusion transcripts. The strong...

The relation between end of induction minimal residual disease and different risk factors in patients with acute lymphoblastic leukemia

Background: Malignant disorder with B or T stem cell basis leads to development and continuation of acute lymphoblastic leukemia (ALL) due to aggregation of blast cells in bone marrow. The environmental, genetic, and demographic factors may influence the disease relapse. The objective of this study was to assess the relation between end of induction minimal residual disease and different risk f...

Evaluation of Relationship between Minimal Residual Disease (MRD) and Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) Using Quantitative Fluorescent PCR

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

MRD diagnostics during the first three months of treatment has proven to be of high value in pediatric acute lymphoblastic leukemia (ALL), because of its potential to recognize subgroups that differ substantially in outcome. Consequently, MRD diagnostics is now being used for treatment intervention, both treatment intensification (including stem cell transplantation) and treatment reduction. Ho...